The Parker Institute for Cancer Immunotherapy and National Resilience Inc. announced a five-year strategic alliance to develop next-generation cancer therapies.
Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.
